KM Research Hub
DIGITIZATION RESULTS

KM 曲线提取结果

共 239 篇,按论文发表时间从新到旧排列。

论文发表日期KM Figure面板成功提取曲线数状态
Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP05 Trial.PMID 40235447 · Ann Surg 2026-Jan-01 1224 提取完成
Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.PMID 40820816 · Haematologica 2026-Jan-01 2161625 质量警告
Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial.PMID 41115255 · J Clin Oncol 2026-Jan 16611 质量警告
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.PMID 41251890 · Adv Ther 2026-Jan 26612 提取完成
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.PMID 41507539 · Nat Cancer 2026-Jan 7303061 质量警告
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.PMID 41514054 · Nat Cancer 2026-Jan 35510 提取完成
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.PMID 41287969 · CA Cancer J Clin 2026 35512 质量警告
Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China.PMID 41625476 · Cancer Commun (Lond) 2026 2446 质量警告
Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial.PMID 41821581 · Cancer Commun (Lond) 2026 2336 提取完成
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.PMID 42282892 · Cancer Commun (Lond) 2026 2213 部分完成
Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201.PMID 41397917 · Oncologist 2025-Dec-27 2225 质量警告
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.PMID 41037766 · J Clin Oncol 2025-Dec-20 1336 提取完成
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.PMID 40991848 · Blood 2025-Dec-18 38816 提取完成
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.PMID 40991874 · J Clin Oncol 2025-Dec-10 1447 质量警告
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma.PMID 41345095 · Blood Cancer J 2025-Dec-04 5101018 质量警告
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.PMID 41339316 · Nat Commun 2025-Dec-03 1111130 质量警告
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008.PMID 40947016 · Ann Oncol 2025-Dec 1112 提取完成
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.PMID 41057655 · Nat Med 2025-Dec 4121221 质量警告
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.PMID 41062831 · Nat Med 2025-Dec 1223 质量警告
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.PMID 41092247 · J Clin Oncol 2025-Dec 1336 提取完成
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.PMID 41109920 · Nat Med 2025-Dec 2334 质量警告
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.PMID 41259897 · ESMO Open 2025-Dec 1336 提取完成
Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.PMID 41270700 · ESMO Open 2025-Dec 1336 提取完成
Tumor-Informed ctDNA in Guiding First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancers.PMID 41287887 · Adv Sci (Weinh) 2025-Dec 310920 部分完成
Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).PMID 41337859 · ESMO Open 2025-Dec 1114 提取完成
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.PMID 41337860 · ESMO Open 2025-Dec 1336 提取完成
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.PMID 40763276 · Blood Adv 2025-Nov-25 1222 提取完成
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.PMID 41082707 · J Clin Oncol 2025-Nov-20 1224 提取完成
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer.PMID 41191939 · N Engl J Med 2025-Nov-06 2223 质量警告
Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.PMID 40207715 · Haematologica 2025-Nov-01 1224 提取完成